The social prescription plan aims to bring about the major shift in perspective needed. More: NHS aims for one link worker per primary care network from July Source: News
read moreAstraZeneca’s PD-L1 inhibitor Imfinzi will be made available on the NHS in England immediately for patients with locally advanced unresectable non-small-cell lung cancer. More: AZ' Imfinzi to be funded for NHS use via CDF Source: News
read moreLatest data from NHS Digital shows an increase in the number of prescription items dispensed in the community, but a drop in their cost to the NHS. More: Number of prescription rises but cost falls again Source: News
read moreWeeks after a California jury hit Johnson & Johnson with a $29 million mesothelioma verdict, the company scored a win close to home. A jury in Middlesex County, New Jersey, cleared the drugmaker in a lawsuit brought by plaintiff Ricardo Rimondi alleging
read moreA filing for ozanimod was initially rejected by the US regulator in February 2017. More: Celgene resubmits MS drug, ozanimod, to FDA Source: News
read moreAimmune to file peanut allergy drug in Europe based on Phase III data showing an improvement in peanut tolerance. More: Phase III results move Aimmune’s peanut allergy drug closer to EU market Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals